发明授权
US06867213B2 (2S)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrhydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use
有权
（2S）-2-（金刚烷-1-基甲氧基羰基氨基）-3-（4-（2-（1,4,5,6-四氢嘧啶-2-基氨基甲酰基）乙基）苯甲酰氨基）丙酸异丙酯，其制备及其 使用
- 专利标题： (2S)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrhydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use
- 专利标题（中）： （2S）-2-（金刚烷-1-基甲氧基羰基氨基）-3-（4-（2-（1,4,5,6-四氢嘧啶-2-基氨基甲酰基）乙基）苯甲酰氨基）丙酸异丙酯，其制备及其 使用
-
申请号： US10398821申请日： 2001-09-27
-
公开(公告)号： US06867213B2公开(公告)日： 2005-03-15
- 发明人: Anuschirwan Peyman , Theodor Wollmann , Gerhard Brejpohl , Jean-Francois Gourvest , Jean-Marie Ruxer , Thomas Gadek , Robert McDowell
- 申请人： Anuschirwan Peyman , Theodor Wollmann , Gerhard Brejpohl , Jean-Francois Gourvest , Jean-Marie Ruxer , Thomas Gadek , Robert McDowell
- 申请人地址： DE
- 专利权人： Aventis Pharma Deutschland GmbH,Genentech Inc.
- 当前专利权人： Aventis Pharma Deutschland GmbH,Genentech Inc.
- 当前专利权人地址： DE
- 代理机构： Muserlian, Lucas and Mercanti
- 优先权： EP00121986 20001010
- 国际申请： PCTEP01/11186 WO 20010927
- 国际公布： WO0230910 WO 20020418
- 主分类号： A61K31/505
- IPC分类号： A61K31/505 ; A61P9/00 ; A61P9/10 ; A61P13/02 ; A61P19/10 ; A61P27/02 ; A61P29/00 ; A61P35/00 ; A61P43/00 ; C07D239/16 ; C07D239/02
摘要：
(2S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its useThe present invention relates to (2S)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester of the formula I and its physiologically tolerable salts, their preparation, their use as pharmaceuticals and to pharmaceutical compositions comprising them. The compound of the formula I and its physiologically tolerable salts are valuable pharmacologically active compounds which can be used, for example, in the treatment or prophylaxis of diseases which can be influenced by inhibiting the vitronectin receptor, for example of bone diseases such as osteoporosis.
公开/授权文献
信息查询
